[WHO classification of Hodgkin's lymphoma and its molecular pathological relevance]
- PMID: 12089788
- DOI: 10.1007/s00292-002-0529-1
[WHO classification of Hodgkin's lymphoma and its molecular pathological relevance]
Abstract
The current WHO classification of Hodgkin's lymphoma (HL) generally distinguishes the relatively rare variant (approximately 5% of all cases of HL) of nodular lymphocyte predominant type from a second group, which comprises classical HL and is separated into four subtypes: lymphocyte rich type, nodular sclerosis type, mixed cellularity type and lymphocyte depleted type. The classical lymphocyte rich subtype is a new entity and based on the typical morphology, can be recognized by definition only by the immunohistochemical characteristics of the Hodgkin and Reed/Sternberg cells (HRS) (CD30+, CD15+, CD20-). Molecular single cell studies are consistent with the dichotomy of HL in nodular lymphocyte predominant and classical types and stress the exceptional position of the former, which shows similarities with non-Hodgkin's lymphomas in several aspects. On the molecular biology level the tumor cells of all kinds of HL turn out to be clonal B cells derived from germinal center cells. However, tumor cells of nodular lymphocyte predominant HL differ from those of classical HL by the pattern of somatic mutations. Considering the inability of HRS cells of classical HL to express a B cell receptor, they should perish under normal conditions. However, they escape from apoptosis by mechanisms so far only partially understood, such as genomic mutations of the l-kappa B gene and the fas receptor gene or probably by down-regulation of B cell markers. In rare cases, HRS cells of HL can also be derived from T cells, as could be demonstrated by single cell analysis. Also, it could be shown by single cell PCR that HL and non-Hodgkin's lymphoma of both B and T cell types can arise from a common precursor. These results suggest that future classifications of HL will not only take into account the morphological and phenotypical profile, but also mechanisms of transformation yet to be discovered.
Similar articles
-
TARC, a CC chemokine, is frequently expressed in classic Hodgkin's lymphoma but not in NLP Hodgkin's lymphoma, T-cell-rich B-cell lymphoma, and most cases of anaplastic large cell lymphoma.Am J Surg Pathol. 2001 Jul;25(7):925-9. doi: 10.1097/00000478-200107000-00011. Am J Surg Pathol. 2001. PMID: 11420464
-
Pathology and "molecular histology' of Hodgkin's disease and the border to non-Hodgkin's lymphomas.Baillieres Clin Haematol. 1996 Sep;9(3):459-77. doi: 10.1016/s0950-3536(96)80021-7. Baillieres Clin Haematol. 1996. PMID: 8922240 Review.
-
Hodgkin's and non-Hodgkin's lymphoma: spectrum of morphologic and immunophenotypic overlap.Ann Diagn Pathol. 1999 Oct;3(5):263-75. doi: 10.1016/s1092-9134(99)80021-5. Ann Diagn Pathol. 1999. PMID: 10556472
-
Typing the histogenetic origin of the tumor cells of lymphocyte-rich classical Hodgkin's lymphoma in relation to tumor cells of classical and lymphocyte-predominance Hodgkin's lymphoma.Cancer Res. 2003 Apr 1;63(7):1644-51. Cancer Res. 2003. PMID: 12670918
-
Hodgkin's disease: classification and differential diagnosis.Mod Pathol. 1999 Feb;12(2):159-75. Mod Pathol. 1999. PMID: 10071341 Review.
Cited by
-
A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma.Clin Lymphoma Myeloma Leuk. 2017 Jun;17(6):347-353. doi: 10.1016/j.clml.2017.05.008. Epub 2017 May 22. Clin Lymphoma Myeloma Leuk. 2017. PMID: 28622959 Free PMC article. Clinical Trial.
-
Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma: From Early Achievements towards New Perspectives.J Oncol. 2019 May 7;2019:9513701. doi: 10.1155/2019/9513701. eCollection 2019. J Oncol. 2019. PMID: 31205470 Free PMC article. Review.
-
MTHFR C677 T gene polymorphism in lymphoproliferative diseases.J Clin Lab Anal. 2006;20(2):37-41. doi: 10.1002/jcla.20103. J Clin Lab Anal. 2006. PMID: 16538645 Free PMC article.
-
The Importance of Excisional Biopsy in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma.Cureus. 2023 Jun 10;15(6):e40225. doi: 10.7759/cureus.40225. eCollection 2023 Jun. Cureus. 2023. PMID: 37435260 Free PMC article.
-
Variable Expression of Notch1 and Pax5 in Classical Hodgkin Lymphoma and Infection with Epstein-Barr in Pediatric Patients.Microorganisms. 2020 Jun 26;8(6):958. doi: 10.3390/microorganisms8060958. Microorganisms. 2020. PMID: 32604737 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous